Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4804 (MIR4804) is a small, non-coding RNA molecule (20-24 nucleotides) transcribed from its gene as a long primary transcript, which is processed into a stem-loop precursor and then into the mature form by Drosha and Dicer RNase III enzymes. Once mature, MIR4804 is loaded into an RNA-induced silencing complex (RISC) where it base-pairs with target mRNAs—most notably the CMKLR1 gene—and inhibits their translation or promotes their degradation. MIR4804 plays a role in human monocyte immune function by regulating cytokine secretion and cell proliferation, and may contribute to immune homeostasis especially in chronic hepatitis B infection. Altered expression of MIR4804 has been associated with immunodeficiency and hair disorders, and predicted functional analysis links this microRNA to cancer and extracellular matrix-receptor interactions[1][2][3][6]. Direct drug interactions and clinical biomarker applications are yet to be established for MIR4804.
Inhibition of target gene CMKLR1 (chemokine-like receptor 1) expression. Translational inhibition of mRNAs via imperfect base pairing. Destabilization of mRNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 4804 (MIR4804).